Development of therapeutic drug for osteoporosis using DHNA

本应用研究旨在验证其作为骨质疏松症治疗剂的作用，特别是作为1,4-二羟基-2-萘酸（DHNA）的一种新的可能性，对骨代谢的影响。在骨质疏松动物模型开始时，通过micro-CT三维骨分析验证了dna对骨质疏松症骨密度的改善结果。结果通过对改善骨质疏松症骨密度的机制分析，通过成骨细胞诱导实验，提高钙化程度，碱性磷酸酶激活度升高得到证实。提示对参与骨形成的破骨细胞有分化抑制作用，促进骨基质的主要是dna含量大于或大于。

This application study was that relevant, to verify the effects of as therapeutic agents for osteoporosis, especially to bone metabolism as a new possibility of 1,4-dihydroxy-2-naphthoic acid of (DHNA). Showed an improvement of bone density of osteoporosis results DHNA administration and verified by three-dimensional bone analysis using micro-CT to the effects of osteoporosis DHNA of osteoporosis in animal models at the beginning. A result of the analysis of mechanisms to improve bone density of osteoporosis of DHNA, increase of calcification degree of osteoblast induction experiments, alkaline phosphatase activation rise was confirmed. Was suggested that there is a differentiation inhibitory effect against osteoclasts involved in bone formation in the promotion of bone matrix mainly DHNA than or more.